What About Existing Databases?
; ; ; ;
We agree that research into and treatment optimization of multidrug resistant tuberculosis can be successfully undertaken only by way of a joint effort.
We were surprised that the review article did not mention representative data collections of patients with MDR-TB and XDR-TB in Germany. From 2004 to 2006, the Tuberculosis Network European Trials-group (TBNET) systematically collected data from patients with MDR-TB and XDR-TB in 27 hospitals and evaluated the therapeutic successes (1). TBNET is a European alliance of doctors in clinical practice as well as scientists; the group’s remit is TB research. The network receives funding from the European Union and is closely linked to the European Respiratory Society. In a study of 4557 TB patients, 177 patients were found to have MDR-TB and 7, XDR-TB. This amounts to two thirds of all patients known to have MDR-TB or XDR-TB in Germany. The mean inpatient stay for XDR-TB is 202 days, and for MDR-TB, 123 days. The expensive inpatient care, comprehensive testing for antibiotic resistance, and the availability of all required medications have yielded excellent treatment results in 89% or 80% of the cases that were subsequently documented. In 2010, TBNET has established a database to capture MDR-TB and XDR-TB in Europe, with the aim to provide a comprehensive prospective and retrospective analysis of MDR-TB and XDR-TB. We are asking our colleagues who treat patients with MDR-TB and XDR-TB to join in the concerted effort and participate in the database project, so as to make a contribution to research into this intractable disease (information at www.tb-net.org or from email@example.com).
Dr. med. Christian Herzmann, MRCP(UK)
Dr. med. Gunar Günther
Dr. med Barbara Eker
Prof. Dr. med. Christoph Lange
23845 Borstel, Germany
Prof. Dr. med. Giovanni Battista Migliori
Fondazione S. Maugeri
Care and Research Institute
Via Roncaccio 16
21049 Tradate, Italia
|1.||Eker B, Ortmann J, Migliori GB, et al. for the TBNET: Multi-drug resistant and extensively drug resistant tuberculosis, Germany. Emerg Infect Dis 2008; 14(11):1700–6. MEDLINE|
|2.||Loddenkemper R, Hauer B: Drug resistant tuberculosis—A world wide epidemic poses a new challenge [Resistente Tuberkulose – Große Herausforderung durch eine Weltepidemie]. Dtsch Arztebl Int 2010; 107(1–2): 10–9. VOLLTEXT|